CD3-specific antibody-induced active tolerance: from bench to bedside
L Chatenoud - Nature Reviews Immunology, 2003 - nature.com
Although they were used initially as non-specific immunosuppressants in transplantation,
CD3-specific monoclonal antibodies have elicited renewed interest owing to their capacity to …
CD3-specific monoclonal antibodies have elicited renewed interest owing to their capacity to …
In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift
Ex vivo programming of T cells can be efficacious but is complex and expensive; therefore,
the development of methods to transfect T cells in situ is important. We developed and …
the development of methods to transfect T cells in situ is important. We developed and …
IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation
CM Tilsed, BA Sadiq, TE Papp… - Proceedings of the …, 2024 - National Acad Sciences
The use of lipid nanoparticles (LNP) to encapsulate and deliver mRNA has become an
important therapeutic advance. In addition to vaccines, LNP-mRNA can be used in many …
important therapeutic advance. In addition to vaccines, LNP-mRNA can be used in many …
Optimization of methods to assess human mucosal T-cell responses to HIV infection
BL Shacklett, O Yang, MA Hausner, J Elliott… - Journal of …, 2003 - Elsevier
The majority of HIV-1 infections occur via sexual transmission at mucosal epithelia lining the
vagina, cervix or rectum. Mucosal tissues also serve as viral reservoirs. However, our …
vagina, cervix or rectum. Mucosal tissues also serve as viral reservoirs. However, our …
CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications
L Chatenoud - Current opinion in immunology, 2005 - Elsevier
The treatment of autoimmune diseases using conventional chemical immunosuppressants
has short-term effects, imposing the need for chronic treatment with its risks of over …
has short-term effects, imposing the need for chronic treatment with its risks of over …
A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost …
J Mpendo, G Mutua, J Nyombayire, R Ingabire… - PloS one, 2015 - journals.plos.org
Background Strategies to enhance the immunogenicity of DNA vaccines in humans include
i) co-administration of molecular adjuvants, ii) intramuscular administration followed by in …
i) co-administration of molecular adjuvants, ii) intramuscular administration followed by in …
Breadth of CD8 T-cell mediated inhibition of replication of diverse HIV-1 transmitted-founder isolates correlates with the breadth of recognition within a comprehensive …
P Hayes, N Fernandez, C Ochsenbauer, J Dalel… - PloS One, 2021 - journals.plos.org
Full characterisation of functional HIV-1-specific T-cell responses, including identification of
recognised epitopes linked with functional antiviral responses, would aid development of …
recognised epitopes linked with functional antiviral responses, would aid development of …
Early HLA-B*57-Restricted CD8+ T Lymphocyte Responses Predict HIV-1 Disease Progression
CA Brennan, FJ Ibarrondo, CA Sugar… - Journal of …, 2012 - Am Soc Microbiol
ABSTRACT Although HLA-B* 57 (B57) is associated with slow progression to disease
following HIV-1 infection, B57 heterozygotes display a wide spectrum of outcomes, including …
following HIV-1 infection, B57 heterozygotes display a wide spectrum of outcomes, including …
In vitro induction of regulatory T cells by anti-CD3 antibody in humans
M Abraham, A Karni, A Dembinsky, A Miller… - Journal of …, 2008 - Elsevier
Therapy with anti-CD3 antibody is effective in controlling models of autoimmune diseases
and can reverse or prevent rejection of grafts. We studied the in vitro immunomodulatory …
and can reverse or prevent rejection of grafts. We studied the in vitro immunomodulatory …
Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition
PJ Hayes, JH Cox, AR Coleman, N Fernandez… - Aids, 2016 - journals.lww.com
Objectives: The ability of HIV-1 vaccine candidates MRKAd5, VRC DNA/Ad5 and
ALVAC/AIDSVAX to elicit CD8+ T cells with direct antiviral function was assessed and …
ALVAC/AIDSVAX to elicit CD8+ T cells with direct antiviral function was assessed and …